PraeDicare company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

praedicarelabs.com

Stage

Grant | Alive

Total Raised

$2.82M

Last Raised

$2.82M | 1 yr ago

About PraeDicare

PraeDiCare provides an in vitro quantitative pharmacology platform that reduces drug development costs by more accurately predicting clinical treatment efficacy and safety in the drug discovery setting.

PraeDicare Headquarter Location

14830 Venture Drive

Dallas, Texas, 75234,

United States

214-649-3834

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing PraeDicare

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PraeDicare is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Latest PraeDicare News

Praedicare Inc. Receives Grant to Evaluate Potential New Drug Regimens for Tuberculosis

Jun 17, 2021

June 17, 2021 07:30 AM Eastern Daylight Time DALLAS--( BUSINESS WIRE )--Praedicare Inc., a CRO using unique pre-clinical laboratory and proprietary mathematical translation models today announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel TB drug regimens using Praedicare’s in vitro hollow fiber model of Tuberculosis (TB) in identifying potential new drug regimens that shorten treatment times for the disease. “We are very pleased and grateful that the Bill & Melinda Gates Foundation recognized the important contribution our earlier HFS-TB studies as well as Praedicare’s unique capabilities to de-risk and speed regimen evaluation especially in the area of this devastating disease,” said Praedicare President and CEO Tawanda Gumbo, MD. The studies will use Praedicare’s capability and expertise with the hollow fiber system model of TB in combination with its clinical mapping algorithms to evaluate new drug combinations for clinical trials based on predictions of the drugs’ effectiveness in shortening duration of therapy. The study will also include pharmacokinetic and pharmacodynamic evaluation of the drugs. TB is caused by Mycobacterium tuberculosis that most often affects the lungs. TB is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. Common symptoms of active lung TB are cough with sputum and blood at times, chest pains, weakness, weight loss, fever and night sweats. TB remains a public health crisis according to the World Health Organization. A total of 1.4 million people died from TB in 2019. Two-thirds of new cases strike India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa. About Praedicare Praedicare Inc. is an end-to-end drug development company, from drug discovery, through preclinical work, to phase IV clinical trials. Praedicare uses preclinical wet lab models mathematically mapped to patients for quantitative prediction of clinical trial outcomes for clinical trial design, significantly reducing clients’ risk, time, and costs of developing safe and effective new drugs. For more information please visit: https://praedicareinc.com/

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.